Bispecific Directory

Built as a quick clinical reference, this BTCE directory helps teams navigate approved agents and emerging combination regimens with side-by-side details on dosing, premedications, CRS incidence, ICANS, adverse events, and additional treatment considerations.

What’s Inside:

BTCEs in Lymphoma: A breakdown of BTCE therapies used in relapsed and refractory lymphoma, including key clinical considerations, treatment positioning, and practical guidance for use in these patient populations. (Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Diffuse Large B-Cell Lymphoma)

BTCEs in Multiple Myeloma: An overview of BTCE options in multiple myeloma, with insights into therapy selection, administration considerations, and management in heavily pretreated patients. (Relapsed/Refractory Multiple Myeloma)

BTCEs in Other Indications: Expanded applications of BTCEs across additional disease states, highlighting where these therapies are being used beyond primary indications and key considerations for each setting.
(MRD-Positive B-Cell Precursor ALL; Relapsed/Refractory B-Cell Precursor ALL; BCP-ALL in Consolidation Phase; HLA-A02:01-Positive; Unresectable/Metastatic Uveal Melanoma; Extensive-Stage Small Cell Lung Cancer After Platinum Progression)

BTCEs in Combination Regimens: An overview of emerging combination approaches involving BTCEs, including how they are being integrated with other therapies and considerations for sequencing and safety.

Clinical Reference Tables & References: Quick-reference tables outlining dosing, administration, adverse events, and monitoring considerations, along with supporting references for further review.